Cells are not the autonomous units they appear to be. A multicellular organism is a constant chemical conversation — every cell continuously receiving signals from its neighbours, the bloodstream, the immune system, and the environment, and deciding — divide, die, differentiate, secrete, contract, store, release. The decisions are made by signaling networks of remarkable complexity: a single human cell expresses thousands of receptor types, hundreds of kinases, and runs dozens of intracellular signaling cascades simultaneously. The discovery that the entire vast machinery of intercellular communication runs on a small number of architectural motifs — receptor-ligand binding, second messengers, phosphorylation cascades, gene-expression changes — is one of the unifying insights of late-twentieth-century biology, and most modern drugs act on these systems.
Cell signaling refers to the molecular processes by which cells receive, process, and respond to signals from their environment, with the general architecture extracellular ligand (hormone, neurotransmitter, growth factor, cytokine) → receptor (typically a membrane protein) → intracellular signaling cascade → cellular response (gene-expression change, secretion, division, motility, apoptosis). The major receptor classes are G-protein-coupled receptors (GPCRs — the largest family, ~800 in humans, targeted by ~35% of all drugs), receptor tyrosine kinases (RTKs — autophosphorylating upon dimerization, the EGFR family heavily targeted in cancer), ion channel receptors (nicotinic acetylcholine, GABA-A, glutamate NMDA/AMPA — fast millisecond responses), nuclear hormone receptors (estrogen, androgen, glucocorticoid, thyroid, vitamin D — direct DNA binding and gene-expression change), and cytokine receptors (typically signaling through JAK/STAT pathways). Second messengers amplify and distribute signals inside the cell — cyclic AMP (downstream of many GPCRs, activates protein kinase A), IP3 (releases calcium from intracellular stores), diacylglycerol (activates protein kinase C), and calcium ions (the most universal intracellular signal) — and kinase cascades run the universal architectures: the MAP kinase cascade (Ras → Raf → MEK → ERK), the PI3K/Akt/mTOR pathway, JAK/STAT, and NF-κB are used across growth, survival, immunity, and differentiation. The signaling layer integrates information rather than relaying it: a single cell's response depends on the combination of signals it is receiving, with cross-talk between pathways extensive, temporal dynamics mattering (sustained vs. pulsatile signals trigger different responses), and spatial localization mattering. Signaling failures underlie much of disease — cancer often involves constitutive activation of growth-factor pathways (oncogenic Ras, BRAF, EGFR mutations), diabetes involves insulin-receptor failure, autoimmune disease involves cytokine dysregulation — and cell-cell communication extends beyond classical signaling via exosomes, direct cell-cell contact signaling (Notch, ephrin) for development, and quorum sensing in bacteria for population-level coordination.
Most drugs target the signaling layer. Beta-blockers block β-adrenergic receptors, antihistamines block H1, antipsychotics block dopamine D2, antidepressants modulate monoamine signaling, and GLP-1 agonists (semaglutide, tirzepatide) activate the GLP-1 receptor and downstream cAMP signaling. Cancer immunotherapy targets the signaling layer specifically: checkpoint inhibitors (pembrolizumab, nivolumab) target the PD-1/PD-L1 axis that tumors exploit to evade immune attack, CAR-T therapy reprograms patient T cells with synthetic chimeric antigen receptors, and tyrosine kinase inhibitors (imatinib, gefitinib, osimertinib, ibrutinib) block specific oncogenic signaling proteins, often producing dramatic responses in cancers harboring matching mutations. JAK inhibitors (tofacitinib, ruxolitinib, baricitinib) treat rheumatoid arthritis, psoriasis, alopecia areata, and severe COVID by blocking cytokine signaling, and gene-expression-based diagnostics (Oncotype DX, MammaPrint) use signaling-pathway activity signatures to guide cancer treatment decisions. AI-driven drug discovery increasingly designs molecules computationally to bind specific signaling-protein conformations, and the vast intercellular conversation biology runs on is the most-druggable surface in medicine.